Protherics Plc - Report of Foreign Issuer (6-K)
June 13 2008 - 3:21PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
13 June 2008
PROTHERICS PLC
(Translation of Registrant’s Name Into
English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by
furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
of 1934.
Yes
No
X
If “Yes” is marked, indicate below the
file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
.
The Registrant is furnishing a copy of its
announcements as reported to the Company Announcements Office of the London Stock
Exchange.
Notification of Director
's
Interests
London, UK; Brentwood, TN, US
:
13
June 2008
-
Protherics PLC ("Protherics" or the "Company"), the
international biopharmaceutical company focused on critical care and cancer,
announces
the vesting,
on 12 June 2008, of a Per
formance Share Award ("Award") to Saul Komisar, Director of
Protherics PLC an
d President of Protherics Inc. under the terms of the Company's
Deferred Bonus Plan. The Award
was made on 12 June 2006 and vests
two years from its Date of Grant
.
Pursuant to the vesting of t
he Award, the Company has today
issued
27,594 Ordinary S
hares to Saul Komisar at a nominal value of 2p per
share.
Following the above transaction,
Saul Komisar
ho
lds 27,594 Ordinary Shares (0.008
% of the total issued or
dinary share capital of the C
ompany of
340,366,655 Ordinary Shares.
The above
disclosure is made
in accordance with Rule 3.1.4R of the
Disclosure and Transparency Rules.
F
or f
urther
i
nformation
please contact
:
|
|
|
Nick Staples,
Director of Corporate
Affairs
|
|
Julie Vickers, Company Secretary
|
|
|
|
|
Financial Dynamics
- press enquiries
|
|
London:
Ben Atwell, Lara Mott
|
|
New York
:
John Capodanno, Jonathan Birt
|
|
Or visi
t
www.protherics.com
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PROTHERICS PLC
|
|
|
|
|
|
|
|
|
|
Date: 13 June 2008
|
|
By:
|
|
/s/ Rolf Soderstrom
|
|
|
|
|
|
Rolf Soderstrom
|
|
|
|
|
|
Finance Director
|
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jul 2023 to Jul 2024
